Jason Coloma, Maze Therapeutics CEO
December 3, 2024 09:07 AM EST
Financing
Startups

Af­ter deal about-face and a spin­out, Maze as­sem­bles $115M Se­ries D

Kyle LaHucik

Senior Reporter

Bay Area biotech Maze Ther­a­peu­tics said Tues­day it com­plet­ed a $115 mil­lion Se­ries D, weeks af­ter split­ting off some of its ALS …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times